MicroRNA-122 (miR-122) facilitates hepatitis C virus replication in vitro. Serum miR-122 has been implicated as a biomarker for various liver diseases; however, its role in chronic hepatitis C remains unclear. To address this issue, 126 patients with chronic hepatitis C who completed pegylated IFN plus ribavirin therapy with sustained virologic response (SVR) or nonresponse (NR) were retrospect...

Successful hepatitis C treatment results in sustained virologic response (SVR), which is tantamount to virologic cure and, as such, is expected to benefit nearly all chronically infected persons. When the US Food and Drug Administration (FDA) approved the first interferon-sparing treatment for HCV infection, many patients who had previously been “warehoused” sought treatment. The infrastructure...

BACKGROUND/AIMS Combined treatment of pegylated interferon-α (PEG-IFN) and ribavirin (RBV) has long been accepted as the standard treatment for chronic hepatitis C virus (HCV) infection. Many predictive factors for treatment response have been identified. The aim of this study was to evaluate the efficacy and safety of combined PEG-IFN plus RBV and to examine the value of serum uric acid as a p...

Successful hepatitis C treatment results in sustained virologic response (SVR), which is tantamount to virologic cure and, as such, is expected to benefit nearly all chronically infected persons. When the US Food and Drug Administration (FDA) approved the first interferon-sparing treatment for HCV infection, many patients who had previously been “warehoused” sought treatment. The infrastructure...

BACKGROUND/AIMS A combination of peginterferon and ribavirin is the standard therapy for chronic hepatitis C (CHC). However, the respective study has not been carried out in a large scale in Korea. The purpose of this study was to collect the studies that have been reported in Korea in order to analyze the therapeutic effect of combination therapy and compare to find racial difference. METHOD...

Introduction: The aim of this study is to assess the therapeutic efficacy and safety of a particular brand ofiFN alpha (PDferon B®) in combination with ribavirin (RlBA) on Iranian patients with chronic hepatitis C (CHC). The addition ofRIBA to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monotherapy to...

Sustained virologic response (SVR) after antiviral therapy for recurrent hepatitis C virus (HCV) infection in liver transplant (LT) recipients is consistently lower than that achieved in non-LT patients. We evaluated efficacy and safety of pegylated interferon (IFN) and ribavirin (RBV) therapy in LT recipients with recurrent HCV and factors associated with SVR. All subjects with histologic evid...

aim : the aim of study was to determine the preliminary result of treatment with pegasys in iranian chronic hepatitis b patients (with genotype d) referred to tehran hepatitis center (thc). background : the genotype of hbv and ethnicity of the patients can affect the response rate to pegasys. patients and methods : during 2006-2008, 12 patients with naïve chronic hepatitis b (genotype d) that r...

background treatment with peginterferon alpha-2b plus ribavirin is the current standard therapy for chronic hepatitis c (chc). however, many host related and viral parameters are associated with different outcomes of combination therapy. objectives the aim of this study was to develop an artificial neural network (ann) model to predetermine individual responses to therapy based on patient’s dem...

background: the effect of il 28 b polymorphism on sustained virology response (svr) in patients with hepatitis c genotype 1 varies among races.â  multiple studies have shown that the svr is two or three times higher in patients with cc genotype compared to those with tt genotype. this study aims to assess the relationship between il 28 b polymorphism and svr in iranian patients. materials and m...